Lower visceral fat as a percentage of body weight may bring benefits that are greater than proportional to total body mass lost.

Nobody's denying this, but the interesting story about GLP-1s is that after you control for fat loss (for instance, by taking cohorts of patients that aren't losing weight) you still get evidence of these off-target effects.